How do I read the evidence?

Approval: find the product, then the use

FDA (the U.S. drug agency) approves a particular product for the uses stated in its label; approval does not cover the broad idea of “peptide therapy.”

Medicine approvals and compounding rules were checked September 26, 2026.

When reading a claim, match its drug name and form to the product being discussed.

Guidance: who wrote it and what can it do?

In May 2026, the national group of medical boards gave boards advice about prescribing. That advice is not itself a law. Each state’s rules determine what can be enforced.

The Arizona Nursing Board also gives advice on how it reads care rules. This advice explains the board’s view; it is not the text of a law.

For a claim about care in Arizona, look for the Arizona rule as well as any general guidance.

Letter: an allegation at a point in time

FDA sends a warning letter to notify a company of problems the agency believes it found. Later replies from the company or updates from FDA may show that the concerns were addressed or that FDA’s view changed.

A company absent from the warning-letter search may simply never have been checked. An empty search is not proof that FDA cleared it.

Search the company’s name in FDA’s warning-letter page. Read any linked response or closing letter, and look for what FDA says about the original concerns.

Report: a signal, not proof of cause

A medicine-problem report alone does not show that the medicine caused the problem. It cannot show how often the problem occurs, either.

Local record: read the date and the scope

Arizona license searches and remote-care rules were checked October 3, 2026.

The public-record rule was checked October 6, 2026.

A public board record is a license check, not a recommendation of the clinician.

For an unclear record, ask the board which license, registration or document is relevant.